-
Leupeptin Hemisulfate Salt for Assay Reliability
2026-09-25
This scenario-driven guide explains where Leupeptin hemisulfate salt can help control proteolysis in cell viability, protein degradation, and selected antiviral workflows—and where its limited membrane permeability calls for caution. It covers assay controls, solution handling, potency context, and practical selection criteria for APExBIO SKU A2570.
-
Ionomycin Free Acid in Calcium–FAK Workflows
2026-09-24
Use Ionomycin free acid to impose a controlled calcium perturbation while testing how calcium dynamics intersect with FAK stability, adhesion, and cell survival. This practical guide separates an exploratory calcium-ionophore workflow from the reference study’s established FAISL–FAK mechanism, with pilot parameters and troubleshooting guidance.
-
Sulfo-NHS-SS-Biotin Kit for Surface Labeling
2026-09-24
Learn how Sulfo-NHS-SS-Biotin Kit (SKU K1006) can support reversible protein labeling alongside cell viability and cytotoxicity workflows. This scenario-based guide covers assay boundaries, surface-labeling design, protocol considerations, data interpretation, and practical kit selection.
-
Vorinostat Beyond Chromatin: Mapping Apoptotic Signaling
2026-09-23
Vorinostat is best known as an HDAC inhibitor, but emerging evidence reframes therapeutic cell death as an actively signaled process rather than a passive consequence of transcriptional collapse. This article connects chromatin remodeling, intrinsic apoptosis, and RNA Pol II biology to propose a more rigorous translational workflow for cancer biology research.
-
QSHXO in MASLD: Autophagy and Ferroptosis
2026-09-23
Liu et al. show that Qushi Huoxue ointment improves steatosis, inflammatory injury, and hepatocyte damage in a mouse model of metabolic associated steatotic liver disease while activating autophagy-associated signals and suppressing ferroptosis-related changes. The study is valuable because it connects biochemical, molecular, and ultrastructural evidence, although causal validation and translation to human MASLD remain incomplete.
-
GW 6471 for Causal PPARα Assays
2026-09-22
GW 6471 converts a PPARα association into a testable causal hypothesis across liver, lipid, and toxicology models. This practical workflow combines pharmacological antagonism with transcriptional, biochemical, and morphological readouts while emphasizing solvent control, fresh dosing, and orthogonal validation.
-
mTOR Inhibition and Mammalian Embryonic Dormancy
2026-09-21
Iyer and colleagues present noninvasive in vitro protocols that place mouse blastocysts, human blastoids, and mouse or human pluripotent stem cells into a reversible diapause-like state through pharmacological mTOR inhibition. The workflow replaces laborious in vivo induction methods with scalable culture-based experiments for studying dormancy, developmental competence, and potential extensions of the preimplantation culture window.
-
Clozapine N-oxide (CNO): Reliable Lab Workflows
2026-09-21
This scenario-driven guide explains how Clozapine N-oxide (CNO), SKU A3317, can support controlled DREADD experiments while protecting cell-viability and cytotoxicity workflows from solvent, storage, and interpretation errors. It combines practical handling guidance with evidence from a 2024 basolateral amygdala study and clear limits on cross-assay conclusions.
-
Cell Senescence β-Galactosidase Staining Kit
2026-09-20
The Cell Senescence β-Galactosidase Staining Kit is an X-gal-based SA-β-Gal staining kit for visualizing senescent cells in cultures and frozen tissue sections. Its pH 6.0 chemistry produces a blue precipitate for light-microscopy scoring, but the result should be combined with orthogonal senescence markers rather than treated as a complete cellular senescence assay.
-
Novel Ziprasidone Impurity: Methods and Significance
2026-09-19
The reference study identified and structurally characterized methylene ziprasidone dimer, an unknown process-related impurity detected during scale-up of ziprasidone hydrochloride. Its integrated HPLC, HRMS, and multidimensional NMR workflow provides a practical model for investigating low-level impurities that may affect pharmaceutical quality and control strategies.
-
p-tau Ser356, NUAK Inhibition, and Alzheimer’s Pathology
2026-09-19
Taylor and colleagues characterize p-tau Ser356 as a Braak stage-associated feature of Alzheimer’s disease pathology and show that it is present in neurofibrillary tangles and near synapses. Their ex vivo experiments further reveal that NUAK inhibition produces model-dependent effects, with selective p-tau Ser356 reduction in human brain slices but broader tau and neuronal protein loss in mouse cultures.
-
Novel Methylene Ziprasidone Dimer: Study Significance
2026-09-18
The 2021 study identified and structurally characterized methylene ziprasidone dimer, a previously unreported process-related impurity detected during ziprasidone hydrochloride scale-up. Its combination of preparative HPLC isolation with HRMS and multidimensional NMR provides a practical model for impurity investigation and pharmaceutical quality control.
-
Ionomycin Free Acid for Calcium–FAK Studies
2026-09-18
Ionomycin free acid gives researchers a direct way to impose a controlled calcium perturbation while tracking FAK stability, Calpain 2 activity, adhesion, and TNBC phenotypes. This workflow extends the FAISL–FAK findings into causal experiments without treating calcium elevation as proof of the mechanism.
-
Kanamycin Sulfate: Selection and MIC Workflows
2026-09-17
Kanamycin Sulfate combines aqueous handling with dependable bacterial selection and susceptibility-testing workflows. This practical guide connects resistance screening, MIC design, protein-synthesis studies, and troubleshooting to the comparative logic of a classic aminoglycoside assay.
-
FAISL Stabilizes FAK in Triple-Negative Breast Cancer
2026-09-17
The 2024 Advanced Science study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by blocking Calpain 2-mediated proteolysis. Its combined transcriptomic, RNA–protein interaction, cellular, patient-data, and nanoparticle-delivery experiments connect FAK protein turnover with triple-negative breast cancer progression and metastasis.